KRT19 and triple-negative breast carcinoma: We used MDA-MB-231 triple-negative breast cancer (TNBC) cells with CRISPR-Cas9 mediated KRT19 knockout (KO) [26] and confirmed complete ablation of K19 expression by Western blotting (Fig. S1A) and RNA-sequencing (RNA-seq) (Table S1).